Myungin Pharm명인제약

Myungin Pharm is highly profitable on its filings but its share price has fallen sharply over the past year.

Myungin Pharm, a Korean maker of central nervous system prescription drugs and some over-the-counter products, reported trailing twelve-month revenue of ₩287B and operating income of ₩92.5B through H1 2026. The shares closed at ₩39,900 on 26 October 2026, down 56.1% over one year and near the bottom of their 52-week range of ₩39,100 to ₩92,600.

What stands out

• Trailing operating margin is 32.2% and net margin is 28.3%, with ROE of 10%, based on the filings.
• Valuation metrics are low on the data given: P/E of 7.2, P/B of 0.7, and a dividend yield of 3.8%.
• The DCF fair value model gives a base value of ₩114,072, with a bear case of ₩88,607 and a bull case of ₩155,504; these are model outputs, not forecasts.
• Liabilities are 6.4% of equity and cash is ₩26.7B; the data shows no borrowings figure.
• Foreign ownership fell from 1.1% to 0.8% over 60 days, and foreign investors were net sellers over the last 20 days, while retail investors were net buyers.
• No recent news headlines are included in the data, so the share price decline is not explained by news in this pack.

What to watch

• The cash dividend and record date decisions from July and August 2026, including the amended dividend filing, and the payment timing.
• Full-year 2026 results and the next quarterly report, to see whether margins hold after the first-half figures.
• Revenue concentration in South Korea and the partnerships aimed at US, European, Chinese and Japanese markets; the data does not show their progress.